Versant Ventures

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S. and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.

Brian Atwood

MD

Mehmet Badur

Senior Associate

Bradley Bolzon

MD and Chairman

Bradley Bolzon

Chairman, MD

Samuel Colella

MD

Jerel Davis

MD

Joel Drewry

Principal

Steven Edelson

VP, Ir and Communications

Markus Enzelberger

Partner

Paul Grayson

Venture Partner

Gianni Gromo

Partner

Katharina Kreymborg

Principal

Rachel Lane

Principal

Bill Link

MD

Barbara Lubash

MD

Guido Magni

Partner

Alex Mayweg

MD

Alex Mayweg

MD

Don Milder

MD

Kirk Nielsen

MD

Clare Ozawa

MD

Robin L. Praeger

MD and CFO

Carlo Rizzuto

Partner

Rebecca Robertson

MD

Charles Warden

MD

Thomas Woiwode

MD

498 past transactions

Inception IBD, Inc.

Inception IBD, Inc. operates in the biotechnology sector and translates academic discoveries in the field of IBD into first-in-class small molecule drugs. The company was incorporated in 2014 and is based in San Diego, California.

Vantage Oncology

Series A in 2002
Vantage Oncology, Inc., offers a comprehensive development, implementation and management solution for radiation oncology. The company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage encourages joint venture ownership opportunities that empower physicians to maintain control of their practice while leveraging the strength of the company's network. Vantage also provides joint venture ownership opportunities for hospitals interested in maximizing the significant benefits created by a strong radiation oncology department.

Monte Rosa Therapeutics

Series B in 2020
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

MedManage Systems

Series D in 2006
MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

Skylight

Series A in 2000
Currently serving the San Francisco Bay Area as a licensed General Contractor, Skylight delivers full service renovations for kitchens, bathrooms and other interior spaces. The Skylight process is fully digital and fully integrated – from planning the space based on lifestyle, to personalized curation of materials, right through to permitting, construction and the final close-out package. Skylight was created to fix the problems with the traditional renovation experience.

RayzeBio

Series C in 2021
RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Fluidigm

Series D in 2005
Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

Veracyte

Series C in 2013
Veracyte, Inc. develops diagnostics for thyroid and non-small cell lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. The company was incorporated in 2006 and is based in South San Francisco, California.

Bright Peak Therapeutics

Series A in 2020
Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

OpGen

Venture Round in 2007
OpGen, Inc is a privately-held company, based in Gaithersburg, MD, and focused on commercializing rapid, high precision solutions for DNA analysis and genomics with the Argus® Whole Genome Mapping System and MapIt® Services. Using the proprietary technologies provided by OpGen, customers in academic, government, biodefense and research labs as well as premier genome centers around the world can view ordered whole genome maps for a wide range of applications including strain typing for early outbreak response, improved sequence assembly of microbial and now large genomes up to 3 Gb and comparative genomics applications. OpGen Community (Linkedin Group) provides an accessible environment to share information, exchange questions and best practices using OpGen’s technologies in a variety of applications.

BlueRock Therapeutics

Series A in 2016
BlueRock Therapeutics LP develops, manufactures, and delivers engineered cell therapies in the fields of neurology, cardiology, and immunology by using CELL+GENE platform. It also offers stable master cell banks, such as, healthy donor cells; induced pluripotent stem cells; allo-engineering for immune evasion; and culturing and expansion. The company was founded in 2016 and is based in Cambridge, Massachusetts with additional offices in New York, New York; and Toronto, Canada. As of September 30, 2019, BlueRock Therapeutics LP operates as a subsidiary of Bayer Aktiengesellschaft.

ParAllele Bioscience

Convertible Note in 2005
Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

RedBrick Health

Series C in 2009
RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

APT Pharmaceuticals

Series B in 2008
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Achaogen

Series B in 2006
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

MedManage Systems

Series E in 2007
MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

Audentes Therapeutics

Series B in 2014
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Inceptus Medical

Series A in 2013
Inceptus is a medical device company incubator with a mission to create and foster innovative concepts into companies by providing a combination of experienced engineering, clinical research expertise, seasoned leadership and strong financial resources. The Inceptus team includes talented medical device engineers, serial entrepreneurs, executive managers and investors with a successful track record in the formation of medical device companies.

Black Diamond Therapeutics, Inc.

Private Placement in 2019
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Immune Design

Series A in 2008
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Gritstone Oncology

Series B in 2017
Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

Amira Pharmaceuticals

Series A in 2006
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Nouscom

Series B in 2017
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Intuity Medical

Venture Round in 2016
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Aprea

Series C in 2018
Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Ambrx, Inc.

Series A in 2005
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Amphora Discovery

Series E in 2006
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Crinetics Pharmaceuticals

Series A in 2015
Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.
VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

Ablation Frontiers

Series C in 2007
Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Impedance Cardiology Systems

Series B in 2006
Impedance Cardiology Systems, Inc. engages in biotechnology and is based in Menlo Park, California.

Sequent Medical

Series C in 2012
Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new option for the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany.

Tarveda Therapeutics

Series D in 2017
Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Lycia Therapeutics, Inc.

Private Placement in 2020
Lycia Therapeutics, Inc. operates as a biotechnology company. Lycia Therapeutics, Inc. was incorporated in 2019 and is based in San Diego, California.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

AAVLife

Series A in 2014
AAVLife provides gene therapy services. It conducts clinical trials. The company was founded in 2014 and is based in Paris, France.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Accelerator Corporation

Venture Round in 2003
Founded in 2003, Accelerator Corporation is a Seattle-headquartered private equity firm with an office in New York and San Diego. The firm is focused on early-stage investments in biotechnology companies.

ROX Medical, Inc.

Series D in 2012
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Acclarent

Venture Round in 2009
Acclarent, Inc. is a medical device company in Menlo Park, CA that was established in June of 2004. The company is dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplastyâ„¢ devices. Through the Balloon Sinuplastyâ„¢ technology and our RelievaÂ:registered: product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. FDA clearances for these devices were completed in 2005 and the products were commercially launched in the US that same year. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT.

Audentes Therapeutics

Series A in 2013
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

APT Pharmaceuticals

Series A in 2007
APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

NewHope Bariatrics

Private Equity Round in 2006
NewHope Bariatrics, Inc. develops and operates ambulatory surgery centers and short-stay surgical hospitals that serve the needs of the morbidly obese. It offers bariatric care services to men, women, and children suffering from obesity.

Ocular Therapeutix

Series C in 2009
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Alexza Pharmaceuticals

Series A in 2002
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.

CODA Biotherapeutics

Private Placement in 2018
CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Quentis Therapeutics

Series A in 2018
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Veran Medical Technologies

Venture Round in 2016
Veran Medical Technologies is an image-guided medical device company that helps physicians diagnose disease and deliver therapies. It develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast-enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. The company was incorporated in 2007 and is headquartered in St. Louis, Missouri.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Nexis Vision

Series A in 2008
Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC.

Metavention, Inc.

Series C in 2018
Metavention, Inc. was incorporated in 2012 and is based in Dover, Delaware.

ROX Medical, Inc.

Series C in 2008
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

ROX Medical, Inc.

Series A in 2004
ROX Medical, Inc. develops interventional vascular therapy devices for uncontrolled hypertension serving customers in the United States and internationally. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was incorporated in 2003 and is based in San Clemente, California.

Twelve

Venture Round in 2012
Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Ocular Therapeutix

Series C in 2011
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.
Celula, Inc., a diagnostic testing services company, focuses on the development and commercialization of diagnostic solutions for high impact diseases. The company offers Integrated Diagnostic Accuracy (IDA) platform, which consists of algorithmically combining technologies in DNA and cellular analysis that produce accuracy compared to current tests; and Integrated Patient Report, which delivers results and facilitates decision making for the patient and the physician. Its products based on IDA technology focus on improving the diagnostic accuracy of women’s diseases, such as gynecologic cancers and non-invasive prenatal diagnosis. The company was incorporated in 2005 and is based in San Diego, California with a development facility in Chengdu, China. As of 2016 Celula, Inc. operates as a subsidiary of NeoSeq Ltd.

Monte Rosa Therapeutics AG

Private Placement in 2020
Monte Rosa Therapeutics AG develops and manufactures cancer drugs that modulates protein degradation pathways. The company is based in Basel, Switzerland.

Nuvaira

Private Placement in 2019
Nuvaira, Inc. develops medical devices to treat obstructive lung diseases. It offers Lung Denervation System, a novel, catheter-based system designed to treat airway nerve hyperactivity and to address chronic obstructive pulmonary diseases by treating overactive airway nerves during a minimally invasive procedure that targets the parasympathetic innervation of the lungs. Nuvaira, Inc. was formerly known as Holaira, Inc. and changed its name to Nuvaira, Inc. in June 2017. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Cotera, Inc.

Venture Round in 2012
Cotera, Inc. designs and develops implants that shift muscles and tendons to redirect the forces they exert on joints. Its portfolio includes Latella device, an implant that is attached to the thigh bone (femur) through a surgical procedure for treating patients with medial knee pain due to osteoarthritis. The company was founded in 2011 and is based in Menlo Park, California.

NeoVista

Series E in 2011
NeoVista Inc is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50. The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Benvenue Medical

Series C in 2011
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Spiration

Series F in 2006
Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

GluMetrics

Series B in 2006
GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Ambrx, Inc.

Series B in 2006
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Monte Rosa Therapeutics

Series A in 2020
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

Amphora Discovery

Series C in 2004
Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Intuity Medical

Series C in 2006
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.

Intersection Medical Inc

Series B in 2006
Intersection Medical, Inc. develops and markets non-invasive medical devices. Its devices help physicians in treating patients with heart failure. The company was founded in 2006 and is based in Carlsbad, California.

Stablix

Series A in 2021
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.
Kyras Therapeutics is a biotech company. According to data from the National Cancer Institute, more than 30 percent of all human cancers are driven by mutations in RAS genes, including 95% of pancreatic, 45% of colorectal, and 35% of lung cancers, among many others.

Intuity Medical

Venture Round in 2012
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

PhaseRx

Series A in 2008
PhaseRx is a startup company based in Seattle focused on the delivery of siRNA and other macromolecular therapeutics. The Company has attracted top-tier venture investors and was founded by its President, Robert Overell, Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company's Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company believes the technology also has significant applications for the delivery of other macromolecular therapeutics.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Lava Therapeutics

Private Placement in 2020
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.

AcuFocus, Inc.

Venture Round in 2014
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

RedBrick Health

Series B in 2007
RedBrick Health, an entirely new kind of health company headquartered in Minneapolis, was founded in 2006 to provide a unique, smart and fair solution to the challenge of rising health care costs. They combine behavior-based health financing with personalized programs and independent advocates, helping employers, health plans, health systems and accountable care organizations experience all the rewards of better consumer health.

SpaceOAR

Debt Financing in 2011
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

NovaLign Orthopaedics

Series B in 2009
NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

CRISPR Therapeutics AG

Series A in 2015
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Century Therapeutics

Series C in 2021
Century Therapeutics, Inc. engages in the development of induced pluripotent stem cell- (iPSC) based drugs for the treatment of hematologic and solid malignancies. The use of iPSC enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply allogeneic, homogeneous therapeutic products. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Bright Peak Therapeutics AG

Bright Peak Therapeutics AG develops engineered cytokines for immuno-oncology indications. The company is based in Basel, Switzerland.
Rennovia, Inc. produces renewable chemicals. It offers adipic acids and adiponitrile for consumer-end products, including carpets, heat-resistant automotive parts, furniture, apparel, footwear, luggage, adhesives, and coatings. Rennovia was incorporated in 2009 and is based in Menlo Park, California.

Calypso Medical

Series C in 2005
Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.

RayzeBio

Series A in 2020
RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Halscion, Inc.

Debt Financing in 2012
HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

CRISPR Therapeutics AG

Series B in 2015
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Anokion SA

Private Placement in 2019
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Akero Therapeutics

Private Placement in 2018
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Advanced ICU Care

Series B in 2008
Advanced ICU Care® is the nation’s leading provider of high acuity telehealth services, contracted to provide care to nearly 100 hospitals in 27 states on a 24 x 7 x 365 basis. Advanced ICU Care is a technology-enabled clinical services provider that employs cutting edge tele-technology, U.S. board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Therachon

Series A in 2015
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Pipeline Therapeutics Inc.

Private Placement in 2018
Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.

CardioNow

Series C in 2001
A healthcare information technology company, provides telecardiology and image archiving solutions for hospitals, cardiovascular core labs, and clinical trial sponsors. It offers storing and sharing of patient images and data for cardiology community. The company was founded in 1999 and is based in Daly City, California.